Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice

Animal models of IBD: linkage to human disease

(2010) Atsushi Mizoguchi et al.   CURRENT OPINION IN PHARMACOLOGY

Inflammatory bowel disease

(2010) Stephen B Hanauer et al.   Expert Review of Clinical Immunology

Dipeptidyl peptidase expression during experimental colitis in mice

(2010) Roger Yazbeck et al.   INFLAMMATORY BOWEL DISEASES

Role of sensory neurons in colitis: increasing evidence for a neuroimmune link in the gut

(2010) Matthias A. Engel et al.   INFLAMMATORY BOWEL DISEASES

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

(2009) Dirk Reinhold et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside

(2009) Marc Vanderheyden et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme

(2009) E. Matteucci et al.   CURRENT MEDICINAL CHEMISTRY

DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue

(2009) K. Kos et al.   DIABETES OBESITY & METABOLISM

Inflammation in the Intestinal Tract: Pathogenesis and Treatment

(2009) Richard S. Blumberg   DIGESTIVE DISEASES

Targeting IL-6 in the treatment of inflammatory and autoimmune diseases

(2009) Changhai Ding et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide

(2009) Wolfgang Jungraithmayr et al.   PEPTIDES

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

(2009) Roger Yazbeck et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Gut???brain axis

(2008) Johannes A Romijn et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice

(2008) Roger Yazbeck   Frontiers in Bioscience-Landmark

Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors

(2008) Ute Bank   Frontiers in Bioscience-Landmark

Sitagliptin Augments Sympathetic Enhancement of the Renovascular Effects of Angiotensin II in Genetic Hypertension

(2008) Edwin K. Jackson et al.   HYPERTENSION

Why study animal models of IBD?

(2008) Warren Strober   INFLAMMATORY BOWEL DISEASES

IL-23/IL-17 immunity as a hallmark of Crohnʼs disease

(2008) Veera Hölttä et al.   INFLAMMATORY BOWEL DISEASES

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The anti-inflammatory effect of neuropeptide Y (NPY) in rats is dependent on dipeptidyl peptidase 4 (DP4) activity and age

(2008) Mirjana Dimitrijević et al.   PEPTIDES

Targeted Deletion of Neuropeptide Y (NPY) Modulates Experimental Colitis

(2008) Bindu Chandrasekharan et al.   PLoS One